Dogwood Q3 Loss Narrows to $4.9M; Going Concern Doubt Persists With Cash Through March 2027
DWTX sits 22% above its 52-week low of $0.901 on elevated volume (2.2× avg).
Summary
Dogwood posted a $4.9M Q3 loss and ended September with $4.9M in cash; with the $5M October placement, runway reaches only March 2027 and management reiterates substantial going concern doubt ahead of November CINP data.
Key Events · Earnings and Guidance · DWTX
-
Q3 Loss Narrows to $4.9M
Net loss was $4,882,942 ($0.14 per share) versus $15,744,616 ($8.20) a year earlier, a comparison inflated by the $12.0M Serpin acquired-IPR&D charge in Q3 2025.
-
Cash Falls to $4.9M
Cash and equivalents were $4,948,266 at September 30, 2026, down from $6,524,744 at December 31, 2025, with $12.8M used in operating activities over nine months.
-
Going Concern Doubt Reaffirmed
Management states cash plus the $5M October 2026 Sealbond placement funds operations only through March 2027, and there is substantial doubt about continuing as a going concern within one year of issuance.
-
IPR&D Impairment Risk Ahead of Data
No Q3 impairment was taken after the $9.2M CINP charge in Q2 2026, but the $57.4M CRP IPR&D asset and $12.0M goodwill remain at risk if November 2026 CINP top-line results disappoint.
Analysis · DWTX · Life Sciences
Dogwood's third-quarter loss shrank to $4.9M from $15.7M a year earlier, but that comparison flatters the company: last year's quarter carried a $12.0M acquired-IPR&D charge from the Serpin license. The number that matters is cash — $4.9M at September 30, plus the $5M Sealbond placement that closed October 26, funds operations only through March 2027. Management states substantial doubt about the ability to continue as a going concern within a year of issuance. The company's remaining value hinges on the Halneuron CINP Phase 2b top-line data expected in November 2026; unfavorable results would likely force another impairment of the $57.4M CRP IPR&D asset and another raise. Any financing before March 2027 will be dilutive at a $1.10 share price.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DWTX was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.8M. The 52-week trading range was $0.90 to $7.04. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.